16 hrs ago
Combo Therapy Best for COPD: Study
A combination drug therapy aimed at opening the airways and reducing inflammation appears to be the best treatment for older adults with chronic obstructive pulmonary disease , especially those with asthma, a new study finds. COPD patients who received a combination of long-acting beta agonists and inhaled corticosteroids were less likely to die or require hospitalization because of their breathing disorder, compared to people receiving only one of the two medications, Canadian researchers report.
Sun Sep 14, 2014
The Motley Fool
COPD Occurs Most Often in These 5 States
A chronic obstructive pulmonary disorder, or COPD, diagnosis may not drive fear into patients like hearing the word "cancer," but make no mistake about it, it's a serious and life-threatening disease that affects people across the U.S. regardless of their sex, age, education level, and socioeconomic status. It's also the primary reason why chronic lower respiratory disease is the third-leading cause of death in this country.
Thu Sep 11, 2014
Medical News Today
Benralizumab Phase II Copd study published
AstraZeneca has announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa study evaluating its novel investigational monoclonal antibody benralizumab in patients with chronic obstructive pulmonary disease . The study, conducted by MedImmune, the company's global biologics research and development arm, evaluated the safety and efficacy of benralizumab in 101 adults with moderate-to-severe COPD and experiencing at least one acute exacerbation requiring oral corticosteroids, antibiotics , or hospitalisation in the past year.
Wed Sep 10, 2014
Interim results for the six months ended 30 June 2014 Well financed to support further development , the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces its interim results for the six months ended . OPERATIONAL HIGHLIGHTS * Development of a novel, commercially scalable, nebulized formulation of RPL554, our lead pipeline candidate.
Tue Sep 09, 2014
Medical News Today
Study: once-daily Ultibro Breezhaler is superior in...
Novartis has presented new data that demonstrated once-daily Ultibro Breezhaler was superior in reducing exacerbations and improving lung function compared to twice-daily Seretide Accuhaler* ), in patients with moderate-to-severe chronic obstructive pulmonary disease . These findings from the head-to-head LANTERN study were presented for the first time at the European Respiratory Society International Congress, September 6-10, in Munich, Germany.
Mon Sep 08, 2014
Novartis Pharmaceuticals Canada Inc. Release: New Data Presented At ...
LANTERN study met primary endpoint demonstrating non-inferiority of UltibroA BreezhalerA 110/50 mcg vs Advair* Diskus* 50/500 mcg followed by statistically significant superiority in post dose trough FEV1 after 26 weeks of treatment in patients with moderate-to-severe COPD1 /CNW/ - Novartis, announces today new data from the LANTERN study that demonstrated UltibroA BreezhalerA was superior in bronchodilation and rate of exacerbations vs Advair* Diskus* ).1 The head-to-head LANTERN study results were presented for the first time at the European Respiratory Society International Congress, .
Hopeful AstraZeneca PLC Unveils Mixed Phase 2 Lung Drug Data
Benralizumab Phase II COPD Study Published In The Lancet Respiratory Medicine Monday, 8 September 2014 Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress AstraZeneca today announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa study evaluating its novel investigational monoclonal antibody benralizumab in patients with chronic obstructive pulmonary disease .
BRIEF-GSK, GOLD, COPD foundation to form expert governance board for COPD assessment test
* Gsk will continue to hold copyright and to provide day-to-day administrative support to protect integrity of cat Further company coverage:
The Financial Mirror
Sosei Group Announces Positive Results f ...
LANTERN study further confirmed superiority of Ultibro A Breezhaler A in improving lung function compared to Seretide A Accuhaler A * in moderate-to-severe COPD patients 1 QUANTIFY study showed superiority of Ultibro A Breezhaler A in lung function and shortness of breath versus tiotropium plus formoterol 2 New data from GLISTEN study will provide important evidence for the benefits of once-daily Seebri A Breezhaler A as add on therapy to LABA/ICS** 3 Novartis has signed an exclusive promotion agreement for Ultibro A Breezhaler A and Seebri A Breezhaler A in the United Kingdom with Pfizer Limited.
Tue Sep 02, 2014
Bronchitis Pictures Slideshow
Bronchitis is an inflammation of the airways in the lungs. The main tubes that air flows through in the lungs are called bronchi, and branching off them are smaller tubes called bronchioles.
Novartis to unveil new data from three key clinical trials at...
Novartis International AG /Novartis to unveil new data from three key clinical trials at European Respiratory Society International Congress 2014 .
Tue Aug 26, 2014
US News & World Report
The ABCs of COPD
Despite falling death rates, COPD is third leading cause of death in the U.S., according to the Centers for Disease Control and Prevention.
Mon Aug 25, 2014
NYU Langone Medical Center to Lead Research to Develop Breath Test...
NYU Langone Medical Center will lead a new clinical initiative -- funded by a $225,000 grant from The National Institutes of Health -- to determine a breath test's effectivness to identify volatile organic compounds in human breath that are biomarkers of chronic obstrutive pulmonary disease .
Thu Aug 21, 2014
Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market
Theravance is probably a familiar name to many of you. The pharmaceutical company has received extensive coverage on Seeking Alpha over the years.